Synonyms: ABX002 | compound 1 [WO2022236133A1]
Compound class:
Synthetic organic
Comment: ABX-002 is an orally delivered, potent CNS-directed thyroid hormone receptor beta (TRβ) agonist. Structurally ABX-002 is an amide prodrug (that can penetrate the blood-brain barrier) which is cleaved by fatty acid amide hydrolase (FAAH) to the active metabolite ABX-002A [1]. It is proposed to promote the oligodendrocyte differentiating and myelinating/remyelinating activites of thyroid hormone in the brain, whilst minimising the peripherally-driven side effects of synthetic thyroid hormone, and was originally intended for the treatment of demyelinating neurodegenerative CNS disorders [1]. ABX-002 is more recently being investigated as a potentiator of serotoninergic (5-HT) antidepressants in the brains of patients with major depressive disorder.
|
|
References |
1. Stearns BA, Baccei JM, Harris JR. (2022)
Fatty acid amide hydrolase (faah) cleavable prodrugs of thyromimetics and combination with peripherally restricted faah inhibitors. Patent number: WO2022236133A1. Assignee: Autobahn Therapeutics, Inc.. Priority date: 06/05/2022. Publication date: 10/11/2022. |